CN113004268B - Thiazole compound for inhibiting tumor cell growth and application thereof - Google Patents
Thiazole compound for inhibiting tumor cell growth and application thereof Download PDFInfo
- Publication number
- CN113004268B CN113004268B CN202110331469.3A CN202110331469A CN113004268B CN 113004268 B CN113004268 B CN 113004268B CN 202110331469 A CN202110331469 A CN 202110331469A CN 113004268 B CN113004268 B CN 113004268B
- Authority
- CN
- China
- Prior art keywords
- thiazole
- thiazole compound
- inhibiting tumor
- cell growth
- fluorophenoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention relates to a thiazole compound for inhibiting the growth of tumor cells and application thereof in the field of pharmaceutical chemistry, wherein the preparation method of the thiazole compound comprises the following steps: taking 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole and piperonyl chloride as raw materials and CH2Cl2As a solvent, triethylamine is used as an acid-binding agent to react the reaction solution at 40 ℃ while stirring for 8-10 hours, and after the reaction, an organic layer is separated and purified to finally obtain the 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-N-piperonyl-aminomethyl) -thiazole. The thiazole compound is prepared into a novel compound containing a thiazole ring and an amide structure through one-step reaction. The novel compound can effectively inhibit the growth of various tumor cells, has obvious inhibition effect on pancreatic cancer cells, and lays a foundation for the development of novel antitumor drugs.
Description
Technical Field
The invention relates to the field of medicinal chemistry, in particular to a thiazole compound for inhibiting the growth of tumor cells and application thereof.
Background
Tumors are the first killers of human health and life at present, the incidence rate of the tumors is second to cardiovascular diseases, and the incidence rate of malignant tumors is in a rapid rising trend along with the influence of environmental pollution or peculiar factors. Malignant tumor has become a common disease and frequently encountered disease seriously threatening human health, along with the development of economy in China, the living standard of people is improved, the environment is worsened, the population is aged, and the malignant tumor has become a main reason for death of residents in China.
Cancer is a disease that is caused by a combination of factors and is characterized by the uncontrolled growth and spread of abnormal cells or tissues. Surgery, radiation therapy, chemotherapy and molecularly targeted drugs are today the few major means of treating cancer. Wherein the surgery and radiotherapy are local treatments, and the chemotherapy and molecular targeted drug treatment are systemic treatments. In addition, endocrine therapy, biotherapy, and the like are also available. Some minimally invasive treatment methods, such as interventional therapy, electrochemical therapy, laser therapy, microwave thermotherapy, ultrasonic thermotherapy, cryotherapy, radiofrequency therapy and the like, can also achieve treatment effects sometimes.
According to the difference of the sources of the medicines in the world, the medicines in the world can be divided into three types of chemically synthesized medicines, biological products and medicines of natural sources. Chemical drugs are still one of the main means of anticancer therapy at present, and the proportion of chemical synthetic drugs in anticancer drugs exceeds 50% in the past year. It is expected that chemically synthesized small molecule drugs will dominate the source of new drug development materials for a long period of time in the future. For example, in 2017, the number of chemically synthesized small-molecule drugs is 7855, the amplification is 4.2%, and the overall amplification is lower than 8.4% of the number of drugs in the world.
Therefore, the preparation of chemically synthesized drugs for alleviating cancer is urgent. Researchers prepare thiazole compounds based on the research thought, and the thiazole compounds have good effect of inhibiting lung cancer cells.
Disclosure of Invention
The invention provides a thiazole compound for preparing a medicament for inhibiting the growth and proliferation of cancer cells, aiming at the requirement of chemically synthesizing an anti-cancer medicament in the prior art.
The invention firstly provides a thiazole compound, which is 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-N-piperonyl-aminomethyl) -thiazole and has a structural formula as follows:
further, the preparation method of the thiazole compound comprises the following steps: taking 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole and piperonyl chloride as raw materials and CH2Cl2As a solvent, triethylamine is used as an acid-binding agent to enable reaction liquid to react at the temperature of 40 ℃ while stirring for 8-10 hours, after the reaction, an organic layer is separated and purified, and finally 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-N-piperonyl-aminomethyl) -thiazole is obtained, wherein the specific process is as shown in the formula:
further, the molar ratio of the 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole, the piperonyl chloride and the triethylamine is 1: (0.5-1).
Further, the separated and purified organic layer is purified by adopting a column layer separation column, and the volume ratio of a column passing solvent is 1: (10-15) A mixed solution of ethyl acetate and petroleum ether.
The novel thiazole compound prepared by the invention has the following beneficial effects:
1) the new compound containing thiazole ring and amide structure is prepared by one-step reaction, the method has mild condition, and the reaction and post-treatment operations are simple;
2) the preparation route of the thiazole compound is simple, and the raw materials and auxiliary materials participating in the reaction are simple and easy to obtain.
The second purpose of the invention is to provide a pharmaceutical application of the thiazole compound, which is mainly used for preparing a pharmaceutical preparation for inhibiting the growth of tumor cells. The medicinal preparation can be prepared into a preparation for inhibiting the growth of tumor cells by adopting a conventional preparation method of a medicinal preparation, taking the thiazole compound and/or the hydrate thereof as active ingredients and adding pharmaceutically acceptable medicinal auxiliary materials, and the specific preparation can be tablets, capsules, powder, syrup, liquid, suspending agents or injection.
Furthermore, the special medicament can be used for preparing a medicinal preparation for inhibiting the growth of tumor cells.
Furthermore, the medicinal preparation can effectively inhibit tumor cells of gastrointestinal stromal tumor, lung cancer, breast cancer and pancreatic cancer. Especially has obvious effect of inhibiting pancreatic cancer tumor cells.
Therefore, the thiazole compound has obvious inhibition effect on the growth of various tumor cells, particularly pancreatic cancer cells, and lays a solid foundation for the development of new antitumor drugs.
Drawings
FIG. 1 is a thiazole compound prepared in example 1Of an object1H-NMR spectrum.
FIG. 2 shows 1 of the thiazole Compound prepared in example 113C-NMR spectrum.
Detailed Description
EXAMPLE 1 preparation of Compound I
The compound 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole (2.94 g, 10 mmol), methylene chloride (20 mL) and triethylamine (1 mL) were sequentially added to a 50mL three-necked flask, and the mixture was magnetically stirred at 40 ℃ to dissolve the compound. Then dropwise adding a mixed solution of piperonyl chloride (1.88 g, 10.2 mmol) and 5 mL of dichloromethane at room temperature while stirring, finishing dropwise adding for about 20 min, continuously stirring at 40 ℃ for reacting for 8h, after the reaction is completed, slowly pouring the reaction liquid into ice water, separating out an organic phase, washing the organic phase to be neutral by using a 5% sodium bicarbonate solution and water respectively, and spin-drying the organic phase to obtain a crude product, wherein the volume ratio of the crude product to the dichloromethane is 1: 12 as column solvent, and obtaining 3.29g of target product of thiazole compound shown in the following structural formula I as yellow solid after column purification with yield of 74.3%.
The product has the following structural formula:
the obtained product is detected and verified by an infrared spectrometer and is shown in figures 1 and 2; the nuclear magnetic verification result is as follows:
1H NMR (400 MHz, DMSO-d 6)δ 7.53 (br, 1H), 7.13 – 6.90 (m, 7H), 6.03 (s, 2H), 5.36 (s, 2H), 4.60 (br, 2H), 3.10 (br, 2H), 1.94 (br, 1H), 0.73 (br, 6H).
13C NMR (101 MHz, DMSO-d 6)δ 170.90, 157.43 (d, J = 237.0 Hz), 154.29, 152.64 (d, J = 12.1 Hz), 147.91 (d, J = 85.2 Hz), 130.85, 121.48, 116.90, 116.82, 116.51, 116.28, 108.52, 108.00, 101.81, 67.60, 65.37, 51.57, 49.40, 20.33, 15.61.
EXAMPLE 2 in vitro antitumor Activity test of thiazole Compound
This example was carried out using the international MTT method and the thiazole compound of example 1 was tested for its tumor cell inhibitory activity in vitro: firstly, inoculating 5 multiplied by 104 tumor cells (gastrointestinal stromal tumor, lung cancer, breast cancer and pancreatic cancer) in logarithmic growth phase on a 96-well cell plate, paving the plate according to 5000 cells (namely 100 mu L per well) per well, adding samples to be detected of thiazole compounds with different concentrations after the cells are attached to the wall, and setting 6 drug concentration gradients (unit mu M) in total, wherein the concentrations are respectively: 1.0, 5.0, 25, 125, 250 and 500; adding DMEM or RPMI1640 culture solution containing 5% FBS into the blank group, and adding complete culture solution containing 1% DMSO into the DMSO group; after 72 hours, adding 20 mu L of 5mg/mL MTT solution into corresponding wells of a 96-well plate, continuing culturing for 3 hours, discarding supernatant in the well plate, adding 150 mu L DMSO for dissolving, detecting the light absorption value at 490nm by using an enzyme-labeling instrument, and calculating the half inhibition concentration IC of the sample to be detected of the thiazole compound on cell growth50。
TABLE 1 IC of thiazole Compounds on respective tumor cells50Value of
Experimental results show that the thiazole compound can inhibit the growth of tumor cells, and particularly has the best inhibition effect on pancreatic cancer cell strains. Has great significance for further developing novel effective cancer treatment drugs. Generally, the thiazole compound and/or the hydrate thereof can be used as an active ingredient by a conventional preparation method of a pharmaceutical preparation, and a pharmaceutically acceptable pharmaceutic adjuvant is added to prepare the preparation for inhibiting the growth of tumor cells, wherein the adopted pharmaceutic adjuvant can be one or more of spice, sweetener, liquid or solid filler and/or diluent, and can be finally prepared into tablets, capsules, powder, syrup, liquid, suspending agents, injection and the like.
The above description is provided for the purpose of describing the preferred embodiments of the present invention in more detail, and it should not be construed that the embodiments of the present invention are limited to the description above, and it will be apparent to those skilled in the art that the present invention can be implemented in many different forms without departing from the spirit and scope of the present invention.
Claims (7)
1. A thiazole compound for inhibiting tumor cell growth, which is 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-N-piperonyl-aminomethyl) -thiazole having the formula:
2. a thiazole compound for inhibiting tumor cell growth according to claim 1, wherein said thiazole compound is prepared by the following steps: taking 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole and piperonyl chloride as raw materials and CH2Cl2As a solvent, triethylamine is used as an acid-binding agent to enable reaction liquid to react at the temperature of 40 ℃ while stirring for 8-10 hours, after the reaction, an organic layer is separated and purified, and finally 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-N-piperonyl-aminomethyl) -thiazole is obtained, wherein the specific process is shown as the formula:
3. a thiazole compound for inhibiting tumor cell growth according to claim 2, wherein said 2- (p-fluorophenoxymethyl) -4- (N-isobutyl-aminomethyl) -thiazole, piperonyl chloride and triethylamine are used in a molar ratio of 1: (0.5-1).
4. A thiazole compound for inhibiting tumor cell growth according to claim 2 wherein the separated and purified organic layer is purified by column chromatography with a column solvent of 1: (10-15) A mixed solution of ethyl acetate and petroleum ether.
5. Use of a thiazole compound according to any of claims 1 to 4 for the preparation of a pharmaceutical formulation for inhibiting tumor cell growth.
6. Use of a thiazole compound according to claim 5, wherein said pharmaceutical formulation is effective in inhibiting tumor cells of gastrointestinal stromal tumors, lung cancer, breast cancer, pancreatic cancer.
7. Use of a thiazole compound according to claim 6, wherein said pharmaceutical preparation has a significant effect on the inhibition of pancreatic cancer tumor cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110331469.3A CN113004268B (en) | 2021-03-29 | 2021-03-29 | Thiazole compound for inhibiting tumor cell growth and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110331469.3A CN113004268B (en) | 2021-03-29 | 2021-03-29 | Thiazole compound for inhibiting tumor cell growth and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113004268A CN113004268A (en) | 2021-06-22 |
| CN113004268B true CN113004268B (en) | 2022-06-21 |
Family
ID=76408348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110331469.3A Active CN113004268B (en) | 2021-03-29 | 2021-03-29 | Thiazole compound for inhibiting tumor cell growth and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113004268B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109705017A (en) * | 2019-01-22 | 2019-05-03 | 中美（河南）荷美尔肿瘤研究院 | A kind of chalcone indole derivatives application in preparation of anti-tumor drugs |
-
2021
- 2021-03-29 CN CN202110331469.3A patent/CN113004268B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109705017A (en) * | 2019-01-22 | 2019-05-03 | 中美（河南）荷美尔肿瘤研究院 | A kind of chalcone indole derivatives application in preparation of anti-tumor drugs |
Non-Patent Citations (1)
| Title |
|---|
| Discovery and biological evaluation of a novel highly potent selective butyrylcholinsterase inhibitor;Qi Li 等;《Journal of Medicinal Chemistry》;20200728;第63卷(第17期);第10030-10044页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113004268A (en) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109134586B (en) | Tripterine derivative and application thereof | |
| CN114195814B (en) | Hydroxy naphthalenone-phenylboronic acid compound, preparation method and application | |
| CN110156822B (en) | Naphthol-phenylboronic acid compound and preparation method and application thereof | |
| JP2019523230A (en) | Anti-metastatic 2H-selenopheno [3,2-h] chromene, their synthesis, and methods of using the same | |
| CN102153508B (en) | 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs | |
| WO2011131102A1 (en) | Preparation method of lactone and use thereof | |
| CN113004268B (en) | Thiazole compound for inhibiting tumor cell growth and application thereof | |
| CN109516926B (en) | Preparation and application of piperlonguminine derivative | |
| CN108530436B (en) | Pyrazole compound and preparation method and application thereof | |
| CN112979638B (en) | Thiazole compound and application thereof | |
| CN104098457B (en) | Tetrahydrocurcumin analogue, preparation and application thereof | |
| CN109232703A (en) | Containing 16- (1 '-aromatic radical -1 ', 2 ', 3 '-triazoles) methylene-androstane -17- ketone derivatives | |
| Xu et al. | Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin‐Isatin Hybrids as Potent Anti‐Breast Cancer Agents | |
| WO2021179884A1 (en) | Oleanolic acid derivative having conjugated diene structure c ring, and preparation method therefor and use thereof | |
| CN115124531A (en) | 4-azatryptanthrin aromatic thioether derivatives, and preparation method and application thereof | |
| CN110028482A (en) | 4- position split melphalan class nitrogen mustard derivatives of brefeldin A and its preparation method and application | |
| CN110028477A (en) | The preparation method and purposes of the 4- position split nitrogen mustard derivatives of a kind of brefeldin A | |
| CN109020904B (en) | 2-aryl-4-aroyl-5-alicyclic amino-2H-triazole compound and application thereof | |
| CN112920149A (en) | Chiral dihydropyran ring derivative and preparation method and application thereof | |
| CN108148080B (en) | Organic golden (III) complex of metal and its synthetic method and application | |
| CN100596294C (en) | 4'-substituted benzyloxy-phenyl butadiene derivatives and preparation and uses thereof | |
| CN103044326A (en) | 5-bromo oxoisoaporphine, and synthesis method and application thereof | |
| CN109369634B (en) | Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity | |
| CN110028480A (en) | 4,7- position split melphalan class nitrogen mustard derivatives of brefeldin A and its preparation method and application | |
| CN112375112B (en) | Benzimidazole derivative BI361 and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230829 Address after: 223100 No. 88 Yandu Road, salt chemical industry development zone, Hongze County, Huai'an City, Jiangsu Province Patentee after: JIANGSU STERRIC CHEMICAL INDUSTRY Co.,Ltd. Address before: 225000 Building 5, Chuangfu workshop, No.1 Chuangfu Road, Hanjiang District, Yangzhou City, Jiangsu Province Patentee before: Yangzhou Prince Pharmaceutical Technology Co.,Ltd. |